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Objective: To assess the relation between a sum score of imaging markers indicative
of cerebral amyloid angiopathy (CAA) and cognitive impairment, stroke, dementia, and
mortality in a general population.
Methods: One thousand six hundred twenty-two stroke-free and dementia-free
participants of the population-based Rotterdam Study (mean age 73.1 years, 54.3%
women) underwent brain MRI (1.5 tesla) in 2005–2011 and were followed for stroke,
dementia and death until 2016–2017. Four MRI markers (strictly lobar cerebral
microbleeds, cortical superficial siderosis, centrum semiovale perivascular spaces, and
white matter hyperintensities) were combined to construct the CAA sum score, ranging
from 0 to 4. Neuropsychological testing measured during the research visit closest
to scan date were used to assess general cognitive function and cognitive domains.
The associations of the CAA sum score with cognition cross-sectionally and with
stroke, dementia, and mortality longitudinally were determined using linear regression
and Cox proportional hazard modeling adjusted for age, sex, hypertension, cholesterol,
lipid lowering medication, atrial fibrillation, antithrombotic medication and APOE-ε2/ε4
carriership. Additionally, we accounted for competing risks of death due to other causes
for stroke and dementia, and calculated absolute risk estimates.
Results: During a mean follow-up of 7.2 years, 62 participants suffered a stroke, 77
developed dementia and 298 died. Participants with a CAA score of 1 showed a lower
Mini-Mental-State-Exam (fully-adjusted mean difference −0.21, 95% CI (−0.42–0.00)
compared to a score of 0. In general, for increased CAA scores we saw a lower g-factor.
The age and sex-adjusted hazard ratios (HRs) per point increase of the CAA score were
1.41 for stroke (95% CI, 0.99–2.00), 1.19 for dementia (95% CI, 0.86–1.65), and 1.26 for
mortality (95% CI, 1.07–1.48). The results for dementia and stroke risk did not differ after
correcting for the competing risk of death. For all outcomes, higher CAA scores showed
higher absolute risk estimates over 10 years.
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Conclusions: Our results suggest that in this community-dwelling population, a higher
CAA score is related to cognitive impairment and a higher risk of stroke, dementia, and
death. The composite CAA score can be used to practically quantify the severity of
vascular brain injury.
Keywords: cerebral small vessel disease, cerebral amyloid angiopathy, sum score, MRI, cognition, stroke,
dementia, mortality
INTRODUCTION
Cerebral amyloid angiopathy (CAA) is a frequent form of
sporadic cerebral small vessel disease caused by accumulation of
amyloid-ß in leptomeningeal and cortical vessels and capillaries
(1, 2). The pathogenesis of CAA is complex and its consequences
can result in cognitive impairment, dementia and stroke with a
high recurrence rate of intracerebral hemorrhages (3, 4).
Brain imaging markers that reflect parenchymal damage
caused by small vessel brain injury have shown to be useful
in a clinical setting to diagnose CAA (2, 5) These markers
visible on magnetic resonance imaging (MRI) include lobar
cerebral microbleeds (CMB), cortical superficial siderosis (cSS),
centrum semiovale perivascular spaces (CSO-PVS) and white
matter hyperintensities of presumed vascular origin (henceforth
WMH) (6, 7) Several markers individually are thought to reflect
different types of small vessel disease. For CAA, cSS has shown
to be highly indicative as a marker in not only patient cohorts,
but also in population-based studies (8–10) Previous studies have
used these individual CAAmarkers to determine their relation to
neurological outcomes (stroke and dementia) and mortality in
both healthy and diseased populations (9, 11–13).
Given that shared risk factors and pathophysiological
pathways of CAA markers are known to overlap, and that often
CAA patients have more than one of the brain imaging markers
present, a recent study developed a composite CAA score by
combining all four markers (CMB, cSS, CSO-PVS and WMH)
(14). The authors concluded that this composite score may better
reflect the overall CAA-related small vessel disease burden in
the brain. Such composite scores reflecting CAA disease burden
could be used in clinical practice or research settings (2, 14).
In a recent study, an association between the proposed CAA
sum score and the prediction of dementia conversion in patients
with probable CAA in absence of intracranial hemorrhage has
been reported (15). Other studies in patients with CAA have
shown that higher CAA scores are correlated with reduced global
brain connectivity (16), and that patients who first present with
transient focal neurological episodes have higher CAA scores
than those who first present with cognitive complaints (17).
In a patient population with ischemic cardioembolic stroke
or transient ischemic attack (TIA) and non-valvular atrial
fibrillation, patients who did not show improvement in their
cognitive assessment in 12 months also had an increased CAA
score (18).
Increasing evidence for the presence of subclinical CAA in
the general population has been supported by high prevalence
of lobar microbleeds identified in individuals over the age of 60
years, and the link with determinants such as APOE genotype
similar to those found in CAA patients (4, 19–22). Though
evidence is at present circumstantial, it is a logical next step
to study whether presence of CAA markers in the general
population leads to an increased risk of neurological events
as well. This was recently shown for presence of microbleeds,
with increased risk of cognitive decline, stroke, dementia
and mortality (23–26). Despite the clear clinical potential of
the developed CAA sum score, its correlations with major
neurological outcomes and death have not yet been assessed in a
general population. We therefore used data from the population-
based Rotterdam Study to investigate the CAA score based on
the four imaging markers in relation to cognitive status and risk
of stroke, dementia, and mortality.
MATERIALS AND METHODS
Study Participants
This study was conducted in the Rotterdam Study, a prospective
population-based cohort study in which participants aged ≥45
years and living in the Ommoord district are examined and
followed for various diseases (27). Imaging of the brain was
incorporated in the study protocol from August 2005 onwards
(28). For the present study, eligible participants of the fifth visit
of the first wave (Rotterdam Study I-5), and second visit of
the second wave (Rotterdam Study II-2) were included. 2015
out of 2,376 eligible participants (84.8%) underwent MRI in
the period between 2005 and 2012. Participants were excluded
if they had insufficient quality scans or missing sequences for
ratings (n = 108), scans with missing PVS and CMB ratings (n
= 94), and scans with MRI-defined large cortical infarcts (n =
53). In addition, participants without informed consent to access
medical records and hospital discharge letters (n = 27) and if
diagnosed with stroke or dementia or had incomplete follow-
up for stroke and dementia diagnoses at time of MRI scan were
excluded (n = 111). This resulted in 1,622 participants free from
stroke and dementia with brain imaging data available for our
analyses (Supplementary Figure 1).
The institutional review board (Medical Ethics Committee)
approved the Rotterdam Study according to the Population Study
Act, executed by theMinistry of Health,Welfare and Sports of the
Netherlands. All participants gave written informed consent.
MRI Scan Protocol and Assessment of
CAA Imaging Markers
MRI of the brain was performed on a 1.5 tesla MRI scanner (GE-
Healthcare). We acquired four high-resolution axial sequences
without administering contrast material: T1-weighted sequence,
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proton density-weighted sequence, fluid-attenuated inversion
recovery sequence and T2∗-weighted gradient-recalled-echo
sequence. Detailed information of the imaging protocol has been
described elsewhere (28).
Trained research physicians rated the presence, number and
location of CMB and PVS, and the presence of cSS and cortical
infarcts on MRI. CMB were defined as focal areas <10mm of
very low signal intensity and rated on T2∗-weighted imaging. We
categorized CMB distribution based on their location in the brain
into strictly lobar, lobar, and deep microbleeds. Strictly lobar
microbleeds restricted to cortical gray matter and subcortical
white matter, whereas lobar microbleeds could present with
or without deep microbleeds. Cortical superficial siderosis was
defined as linear hypointensities with gyriform patterns over the
cerebral cortex on T2∗-weighted images (8) PVS were defined as
linear, ovoid or round-shaped hyperintensities of≥1 and<3mm
and counted in the centrum semiovale, basal ganglia, hippocampi
and midbrain on proton density-weighted images (29) PVS were
counted on a single, predefined slice in the centrum semiovale
(the slice 1 cm above the uppermost part of the lateral ventricles)
and basal ganglia (the slice with the anterior commissure). For
the hippocampi and midbrain, all PVS were counted in the
anatomical areas. For this study we only used CSO-PVS and
categorized the PVS in a validated visual rating scale of 0 to 4,
defined as 0=no PVS; 1=<10 PVS; 2=11–20 PVS; 3=21–40 PVS
and 4=>40 PVS (30).
Quantitative measurements of WMH were obtained using
a validated automated segmentation method (31). Intracranial
volume (ICV) was defined as the summation of graymatter, white
matter, and cerebrospinal fluid. Cortical infarcts were defined
as focal lesions with tissue loss showing involvement of cortical
gray matter.
CAA Score
A simplified version of the CAA sum score (henceforth referred
to as the CAA score) proposed by Charidimou et al. consisted of
scoring the presence of strictly lobar CMB, cSS, CSO-PVS, and
WMH, with a total score that ranged from 0 to 4 (Figure 1) (14).
One point was given to the CAA score for presence of strictly
lobar microbleeds and another point was given if any cSS was
present. PVS categories of≥21 CSO-PVS were awarded with one
point to the score. We computed WMH quartiles after dividing
total WMH volume by ICV. WMH burden in third or fourth
quartiles were awarded with a point to the score.
Modified Boston Criteria Score
In clinical practice, the modified Boston criteria is a tool to aid
diagnose of CAA in patients. Therefore, we also explored the
application of the modified Boston criteria in our population,
and its relation with clinical outcomes. To operationalize this,
the modified Boston criteria score was computed as an ordinal
score ranging from 0 to 2. One point was given to this score
if a single lobar microbleed was present or if cSS was present
(representing possible CAA in the modified Boston criteria) (5).
Two points were given to the modified Boston score if multiple
lobar or cerebellar microbleeds were present or if a single lobar
microbleed and cSS were present (i.e., probable CAA in the
modified Boston criteria).
Assessment of Cognitive Functioning
The cognitive assessment at one time-point, during the
research visit closest to MRI date, included Mini-Mental State
Examination (MMSE), letter-digit-substitution task (LDST),
word fluency test (WFT), Stroop test, 15-word verbal learning
test (15-WLT) and Perdue Pegboard test. For global cognition,
we computed a standardized composite score (g-factor) with
principal component analysis on the adjusted Stroop interference
subtask, LDST, WFT, delayed recall of the 15-WLT, and Perdue
Pegboard). The g-factor explained 43.1% of the total variance in
cognitive test scores in our population. We combined different
tests to construct compound scores for executive function
(average Z-score of Stroop interference subtask, LDST, and
WFT), information processing speed (average Z-score of Stroop
reading and color-naming subtask, and LDST), memory (average
Z-score of immediate and delayed recall of the 15-WLT), and
motor speed (average Z-score of Perdue Pegboard test). New
Z-scores were calculated for each compound score.
The median time between cognitive assessment and the MRI
scan was 0.4 years (interquartile range: 0.1–1.0 years).
Assessment of Stroke
History of stroke was assessed at study entry using home
interviews and reviewing medical records. Stroke was defined
as a syndrome of rapidly advancing clinical signs of focal
or global disturbance of cerebral function lasting ≥24 h or
cause death with no apparent cause other than of vascular
origin, in accordance with World Health Organization criteria.
Continuous monitoring for occurrence of stroke was realized
through automated linkage of general practitioners’ (GPs) files
with the study database (32). Regular checking of medical
files by contacting their treating physicians were done for
participants who moved out of the district or into nursing
homes. Research physicians reviewed all potential stroke cases
using hospital discharge letters, information from GPs and from
nursing home physicians. An experienced vascular neurologist
verified the stroke diagnoses, these were classified as ischemic
or hemorrhagic based on neuroimaging reports or hospital
discharge letters and unspecified if these were absent.
Follow-up started on the date that participants received
brain imaging. Participants were followed until date of stroke
occurrence, date of death, date of last contact in case of loss to
follow-up, or January 1st 2016, whichever came first. Follow-up
was complete for 11564.8 (96.9%) of potential person-years.
Assessment of Dementia
Participants were screened for dementia at baseline and during
visits to the study center for incident and prevalent dementia.
They underwent the MMSE and the Geriatric Mental Schedule
(GMS). Subjects with MMSE<26 or GMS score>0 underwent
further investigation and informant interview including the
Cambridge Examination for Mental Disorders of the Elderly.
Standard criteria were used for dementia (Diagnostic and
Statistical Manual of Mental Disorders, version III, Revised),
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FIGURE 1 | Magnetic Resonance Imaging (MRI) features of the cerebral amyloid angiopathy (CAA) score.
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Alzheimer’s disease (National Institute of Neurological and
Communicative Disorders and Stroke-Alzheimer’s Disease
and Related Disorders Association), and vascular dementia
(National Institute of Neurological Disorders and Stroke and
Association Internationale pour la Recherché et l’Enseignement
en Neurosciences). Continuous monitoring for dementia
was accomplished through electronic linkage of the center
with medical records from GPs and the regional institute for
outpatient mental health care. Cognitive testing and clinical
neuroimaging were used, if available, to diagnose dementia
subtypes. Final diagnosis was made according to international
criteria and established by a consensus panel led by a consultant
neurologist (33).
Incident dementia follow-up started on the date that
participants came for brain MRI. Follow-up of dementia was
until January 1st 2016, participants were censored at date of
dementia diagnosis, death, loss to follow-up, whichever came
first. Until January 1st 2016, follow-up was complete for 11273.6
(94.9%) of potential person-years.
Assessment of Mortality
Information on vital status of participants was collected from
municipal health authorities in Rotterdam and updated for all-
cause mortality on a monthly basis in the Rotterdam Study.
Continuous reporting for incident events was achieved through
automatic linkage of GPs files and verified by checking medical
records to gather information on cause of death.
Participants were followed up from date of MRI scan until
date of death, loss to follow-up or June 16th 2017, whichever
came first. Follow-up was complete for 12110.2 (100%) of
potential person-years.
Assessments of Covariates
Participants were interviewed during center visits preceding
brain MRI, and underwent laboratory and physical examinations
for information on demographic, genetic and cardiovascular
risk factors.
History of TIA and coronary heart disease, atrial fibrillation,
diabetes mellitus, hypertension, serum total cholesterol, blood
pressure and antithrombotic and lipid lowering medication,
smoking, APOE-ε2/ε4 carriership, and education were used as
covariates in this study. Definitions of included variables are
presented in the online-only Supplementary Material.
Statistical Analysis
Differences in baseline variables between CAA scores were
assessed using chi-square test, Fisher’s exact test or ANOVA. 5-
fold multiple imputations were used for missing covariates
[ranging from 0.001% (hypertension) to 10.6% (atrial
fibrillation)] based on determinants, outcome status, and
follow-up time. Distribution of covariates in imputed and
non-imputed datasets showed no differences.
CAA scores of 3 and 4 occurred infrequently and were
therefore combined. We investigated the CAA score and
modified Boston criteria score in an ordinal manner and
continuously in our analyses. Superficial siderosis and WMH
were the strongest determinants amongst the individual CAA
markers. We evaluated the dependency of the score on cSS and
WMH by separately excluding one of the markers from the score,
resulting in a maximum score of 3 in repeated analyses.
Multiple linear regression models were applied to investigate
the cross-sectional association between the combined CAA score
and cognitive functioning. Cox proportional-hazards models
were used to investigate the association between the combined
CAA score, the modified Boston criteria score and individual
CAA markers with the risk of stroke, dementia, or mortality. All
models were corrected for age and sex (model 1). Additionally,
we corrected for hypertension, cholesterol, lipid lowering and
antithrombotic medication, history of atrial fibrillation, and
APOE-ε2/ε4 carriership based on literature (model 2) (1, 3). The
proportional-hazards assumption was tested using Schoenfeld
residuals and no violations were identified. Further, Fine-
Gray modeling was used to perform competing risk analyses
by modeling subdistribution hazards to assess mortality as a
competing risk for stroke and dementia (34). Goodness-of-fit
tests revealed no linear, quadratic or log time-varying effects
of categorical and continuous CAA score (p > 0.1 for all
analyses) for the Fine-Gray models. After adjusting for model
2, absolute risks of stroke and dementia were estimated up
to 10 years with Fine-Gray modeling and for mortality with
Cox modeling according to the CAA score. We used bootstrap
resampling (n = 5,000) to estimate confidence intervals of the
absolute risk estimates. Models did not converge for 1-year
absolute risk estimates of stroke and dementia and 2-year risk
estimates of stroke, due to low number of incident events and
were excluded.
We studied the relation of the CAA score with subgroups
of the neurological outcomes and mortality, namely ischemic
and hemorrhagic stroke, Alzheimer’s disease, and cardiovascular
mortality. Finally, we explored non-linear effects of age in our
models by adding age-squared or natural cubic splines with 3
degrees of freedom.
All analyses were performed using statistical software
packages SPSS (version 24.0) and R using cmprsk (35),
riskRegression (36), and nricens (37) packages (version 3.5.2,
R Foundation for Statistical Computing, R Core Team (38),
Vienna, Austria). The significance threshold was set at P < 0.05.
The Strengthening the Reporting of Observational Studies in
Epidemiology statement was used as guideline (39).
RESULTS
Baseline Characteristics
Characteristics of the study population are shown in Table 1.
Of the total of 1,622 participants, 54.3% were women and the
average age at baseline was 73.1 years (SD 7.6). The majority of
the participants had a CAA score of 1 (n = 753) and only one
participant had a score of 4. More men than women had scores
of 1 and 2, andwomenmore often had CAA scores of 0 and 3 (p=
0.002). The MMSE score ranged between 12.0 and 30.0 (median
28.0). Mean follow-up time was 7.2 years for stroke, dementia
and death. In our study, 62 participants suffered from a stroke,
77 developed dementia and 298 died.
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TABLE 1 | Baseline characteristics of the study population.
All participants, N = 1622
Age, years 73.1 (7.6)
Female sex, n 880 (54.3)
History of transient ischemic attack, n 110 (6.8)
History of coronary heart disease, n 146 (9.0)
History of atrial fibrillation}, n 86 (5.9)
History of diabetes mellitus}, n 185 (11.6)
Hypertension}, n 1,276 (78.8)
Systolic blood pressure}, mmHg 148.5 (20.7)
Diastolic blood pressure}, mmHg 82.5 (10.8)
Body mass index, kg/m2 27.4 (3.8)
Total cholesterol}, mmol/L 5.5 (1.0)
Blood pressure lowering medication}, n 756 (46.7)
Antithrombotic medication}, n 454 (28.1)
Serum lipid lowering medication}, n 441 (27.3)
Smoking status}, n
Never 513 (31.9)
Current 221 (13.7)
Former 875 (54.4)
APOE-ε2/ε4 carrier}, n 643 (40.5)
Education}, years 12.3 (3.7)
Imaging markers
Strictly lobar cerebral microbleeds, n 284 (17.5)
Cortical superficial siderosis, n 10 (0.6)
Centrum semiovale perivascular spaces, n 1,490 (93.0)
0 113 (7.0)
≤10 1,120 (69.1)
≥11–20 316 (19.5)
≥21–40 73 (4.5)
WMH, mL* 4.4 [2.4–9.1]
First quartile 0.4–2.4
Second quartile 2.5–4.4
Third quartile 4.5–9.1
Fourth quartile 9.2–135.1
Non-imputed values are means (standard deviation) or numbers (valid percentages).
*Intracranial volume-corrected white matter hyperintensities (WMH) shown in median and
interquartile range with separate quartile ranges.
}Data was missing for the following variables: history of atrial fibrillation (10.6%), history
of diabetes mellitus (1.8%), hypertension (0.1%), systolic blood pressure (0.1%), diastolic
blood pressure (0.5%), total cholesterol (0.4%), smoking status (0.8%), blood pressure
lowering medication (0.2%), antithrombotic medication (0.6%), serum lipid lowering
medication (0.5%), APOE-ε2/ε4 carriership (2.2%), and education (1.9%).
Association of CAA Score With Cognitive
Functioning
Participants with a CAA score of 1 showed a significant lower
MMSE after adjustments for cardiovascular factors and APOE-
ε2/ε4 carriership compared to those with a score of 0 (mean
difference−0.21, 95% CI (−0.42–0.00), Figure 2). An increasing
CAA score related to a lower g-factor, yet none of the associations
with g-factor were significant.
Overall, the associations of cognitive domains were also not
significant, only for the memory domain, having a CAA score
of 1 compared to a score of 0 showed a significant impairment
persisting after further adjustments in model 2 (Figure 3).
Association of CAA Score With Stroke,
Dementia, and Mortality
Higher CAA scores were related to higher HRs for stroke,
dementia and mortality (Table 2). After further adjustments in
model 2, having a score of 1 remained significant for stroke. Risk
for developing dementia was highest for participants with CAA
scores of 3–4 and remained significant after correction in model
2 [HR 3.25, 95%CI (1.00–10.54)].When comparing subjects with
a CAA score of 2 compared to a score of 0, associations were seen
with mortality after additional adjustments for cardiovascular
risk factors and APOE-ε2/ε4 carriership.
Excluding cSS from the combined CAA score attenuated
associations of the scores for all outcomes and only
remained significant for score 1 and MMSE and score 1
and stroke after further adjustments (model 2, Table 3 and
Supplementary Table 2). After excluding WMH from the CAA
score, all associations again attenuated and none remained
significant (Supplementary Tables 3, 4).
Association of the Modified Boston Criteria
Score With Stroke, Dementia, and Mortality
The modified Boston criteria score showed higher risk for
developing dementia with a score of 2 (probable CAA) and
for death with a score of 1 (possible CAA) after adjusting
for cardiovascular risk factors and APOE-ε2/ε4 carriership
(Supplementary Table 5). The HRs of the Boston criteria
score were lower compared to the CAA score, particularly
for stroke.
Association of Individual CAA MRI Markers
With Stroke, Dementia, and Mortality
CSO-PVS, cSS, and WMH were related to all outcomes
(Table 4). Strictly lobar microbleeds were only related with
mortality. Ten participants had superficial siderosis and this
marker showed the highest risk among all markers for all
outcomes. Participants with cSS had a 2.2–5.5 times higher
risk of developing an event in our population. These relations
remained significant for stroke and mortality after correcting
for cardiovascular risk factors and APOE-ε2/ε4 carriership.
Other significant associations were found for WMH and
stroke (model 2).
Association of CAA Score With Stroke and
Dementia Adjusted for the Competing Risk
of Mortality and Absolute Risk Estimations
for All Outcomes
The associations between the CAA score and stroke and
dementia slightly attenuated after correcting for the competing
risk of death (Table 5).
For all outcomes over 10 years, higher CAA scores noted
increased risk estimates (Figure 4).
Subgroup and sensitivity analyses are presented in the online
Supplementary Material.
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FIGURE 2 | Forest plots of associations between the cerebral amyloid angiopathy score and cognitive measures. CI, confidence interval; CAA, cerebral amyloid
angiopathy. Model 1: adjusted for age and sex. Model 2: adjusted for age, sex, hypertension, cholesterol, lipid lowering medication, history of atrial fibrillation,
antithrombotic medication, and APOE-ε2/ε4 carriership. (A) Mini-Mental State Examination. (B) G-factor.
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FIGURE 3 | Forest plots of associations between the cerebral amyloid angiopathy score and specific cognitive domains. CI, confidence interval; CAA, cerebral
amyloid angiopathy. Model 1: adjusted for age and sex. Model 2: adjusted for age, sex, hypertension, cholesterol, lipid lowering medication, history of atrial fibrillation,
antithrombotic medication and APOE-ε2/ε4 carriership. (A) Executive function, (B) information processing speed, (C) memory, and (D) motor speed.
DISCUSSION
We found that a higher imaging-based CAA score relates to
cognitive impairment and a higher risk of stroke, dementia,
and mortality in our community-dwelling population. Our study
is the first study to apply the proposed CAA sum score in a
non-diseased population.
Previous studies have investigated the CAA score in patients
with CAA (or probable CAA), ischemic cardioembolic stroke, or
TIA with non-valvular atrial fibrillation (14–18). Patients with
an ischemic cardioembolic stroke or TIA with atrial fibrillation
were also more likely to have higher CAA scores and persistent
cognitive impairment over a 12-month period (18). They found
the CAA score to be associated to cognitive impairment, although
the sample size of the study was small (N = 117). We found a
relation with having a CAA score of 1 and a significant lower
MMSE and a significant impairment of the memory domain with
a trend of an increasing CAA score leading to a lower g-factor.
Even though these observations were cross-sectional and overall
not significant, they were in the direction of our hypothesis.
Lower test scores for memory, executive function and processing
speed have previously been described in patients with CAA
without dementia (40). The pattern we observed for cognitive
impairment in our population could have several explanations.
Application of the CAA score to a general population could
reflect non-CAA etiology compared to applying the score in
a population with CAA patients and not lead to the expected
pattern of cognitive impairment as seen in CAA pathology.
Another explanation could be the long latency period of CAA for
cognitive changes in a subclinical population.
In our study, of all the outcomes, dementia had the strongest
association with the CAA score after adjusting for cardiovascular
factors and APOE-ε2/ε4 carriership [HR 3.25, 95% CI (1.00–
10.54)]. The study by Banerjee et al. (18) also examined the
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TABLE 2 | The association of the cerebral amyloid angiopathy score with stroke, dementia, and mortality.
N n Stroke
HR (95%CI)
n Dementia
HR (95%CI)
n Mortality
HR (95%CI)
Model 1
CAA score
0 666 14 1.00 (reference) 20 1.00 (reference) 76 1.00 (reference)
1 753 38 2.22 (1.17–4.21)* 45 1.45 (0.83–2.51) 162 1.34 (1.00–1.78)*
2 185 9 2.08 (0.86–5.02) 8 0.86 (0.37–2.02) 53 1.66 (1.15–2.40)*
3–4 18 1 2.04 (0.26–15.95) 4 4.61 (1.51–14.08)* 7 1.70 (0.77–3.74)
Continuous
CAA score 1,622 62 1.41 (0.99–2.00) 77 1.19 (0.86–1.65) 298 1.26 (1.07–1.48)*
Model 2}
CAA score
0 651 13 1.00 (reference) 18 1.00 (reference) 75 1.00 (reference)
1 738 38 2.18 (1.13–4.22)* 44 1.52 (0.85–2.72) 160 1.28 (0.96–1.71)
2 180 9 2.01 (0.82–4.92) 8 0.90 (0.38–2.15) 51 1.49 (1.02–2.17)*
3–4 18 1 1.48 (0.18–11.89) 4 3.25 (1.00–10.54)* 7 1.34 (0.60–3.00)
Continuous
CAA score 1,587 61 1.33 (0.93–1.89) 74 1.16 (0.84–1.60) 293 1.18 (1.00–1.39)*
N, number of participants; n, number of events; HR, hazard ratio; CI, confidence interval; CAA, cerebral amyloid angiopathy.
Model 1: adjusted for age and sex.
Model 2: adjusted for age, sex, hypertension, cholesterol, lipid lowering medication, history of atrial fibrillation, antithrombotic medication, and APOE-ε2/ε4 carriership.
}Data missing for APOE-ε2/ε4 carriership n = 35.
*P < 0.05.
TABLE 3 | The association of cerebral amyloid angiopathy score excluding cortical superficial siderosis with stroke, dementia and mortality.
N n Stroke
HR (95%CI)
n Dementia
HR (95%CI)
n Mortality
HR (95%CI)
Model 1
CAA score excluding cSS
0 667 15 1.00 (reference) 20 1.00 (reference) 77 1.00 (reference)
1 755 38 2.05 (1.09–3.82)* 45 1.44 (0.83–2.50) 162 1.32 (0.99–1.75)
2–3 200 9 1.73 (0.72–4.12) 12 1.18 (0.56–2.53) 59 1.62 (1.13–2.32)*
Continuous CAA
score excluding cSS 1,622 62 1.37 (0.94–2.02) 77 1.12 (0.79–1.59) 298 1.27 (1.07–1.52)*
Model 2}
CAA score excluding cSS
0 652 14 1.00 (reference) 18 1.00 (reference) 76 1.00 (reference)
1 740 38 2.00 (1.05–3.80)* 44 1.50 (0.84–2.68) 160 1.26 (0.95–1.68)
2–3 195 9 1.60 (0.66–3.88) 12 1.18 (0.54–2.57) 57 1.43 (0.99–2.06)
Continuous CAA
score excluding cSS 1,587 61 1.31 (0.89–1.94) 74 1.11 (0.78–1.59) 293 1.20 (1.00–1.44)
N, number of participants; n, number of events; HR, hazard ratio; CI, confidence interval; CAA, cerebral amyloid angiopathy; cSS, cortical superficial siderosis.
Model 1: adjusted for age and sex.
Model 2: adjusted for age, sex, hypertension, cholesterol, lipid lowering medication, history of atrial fibrillation, antithrombotic medication and APOE-ε2/ε4 carriership.
}Data missing for APOE-ε2/ε4 carriership n = 35.
*P < 0.05.
cerebral small vessel disease (CSVD) score in patients with atrial
fibrillation-related ischemic stroke or TIA. The CSVD score is
a more well-known sum score to capture the global burden
of small vessel disease in the brain (41). Previously, we also
investigated the CSVD score in the general population and found
that stroke was correlated strongest with this score amongst the
outcomes for stroke, dementia and mortality in our population
[adjusted for the Framingham Stroke Risk Profile, HR 3.47
(1.33–9.06)] (42). Since it is hypothesized that composite scores
reflect the overall disease burden better, this can indicate that
different combinations of individual markers reflect different
pathological mechanisms even when markers co-occur in the
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TABLE 4 | The association of cerebral amyloid angiopathy MRI markers with stroke, dementia and mortality.
N n Stroke
HR (95%CI)
n Dementia
HR (95%CI)
n Mortality
HR (95%CI)
Strictly lobar cerebral microbleeds
Nonea 1.00 (reference) 1.00 (reference) 1.00 (reference)
≥1, model 1 284 8 0.64 (0.30–1.34) 15 0.96 (0.54–1.70) 67 1.17 (0.89–1.54)
≥1, model 2} 277 8 0.61 (0.29–1.30) 15 0.95 (0.54–1.69) 65 1.10 (0.83–1.46)
Cortical superficial siderosis
None 1.00 (reference) 1.00 (reference) 1.00 (reference)
Present, model 1 10 3 7.11 (2.17–23.33)* 3 4.88 (1.51–15.78)* 8 2.66 (1.31–5.43)*
Present, model 2} 10 3 5.49 (1.56–19.35)* 3 3.07 (0.90–10.42) 8 2.16 (1.03–4.54)*
Centrum semiovale perivascular spaces
≤20 1.00 (reference) 1.00 (reference) 1.00 (reference)
≥21, model 1 73 4 1.34 (0.49–3.70) 5 1.19 (0.48–2.95) 20 1.18 (0.74–1.87)
≥21, model 2} 72 4 1.27 (0.46–3.53) 5 1.14 (0.46–2.86) 20 1.18 (0.74–1.88)
White matter hyperintensities
1st and 2nd quartiles 1.00 (reference) 1.00 (reference) 1.00 (reference)
3rd and 4th quartiles,
model 1
811 44 2.29 (1.27–4.13)* 51 1.35 (0.81–2.25) 195 1.34 (1.04–1.72)*
3rd and 4th quartiles,
model 2}
794 44 2.19 (1.19–4.02)* 50 1.35 (0.79–2.30) 191 1.24 (0.96–1.60)
MRI, magnetic resonance imaging; N, number of participants; n, number of events; HR, hazard ratio; CI, confidence interval.
Model 1: adjusted for age and sex.
Model 2: adjusted for age, sex, hypertension, cholesterol, lipid lowering medication, history of atrial fibrillation, antithrombotic medication and APOE-ε2/ε4 carriership.
aNone strictly microbleeds include no microbleeds and microbleeds at other locations like deep and infratentorial microbleeds.
}Data missing for APOE-ε2/ε4 carriership n = 35.
*P < 0.05.
TABLE 5 | The association of cerebral amyloid angiopathy score with stroke and
dementia after adjusting for the competing risk of mortality.
N n Stroke
sHR (95%CI)
n Dementia
sHR (95%CI)
Model 1
CAA score
0 666 14 1.00 (reference) 20 1.00 (reference)
1 753 38 2.19 (1.14–4.22)* 45 1.39 (0.78–2.47)
2 185 9 2.00 (0.81–4.95) 8 1.24 (0.34–1.95)
3–4 18 1 2.02 (0.27–15.37) 4 4.56 (1.30–16.07)
Continuous
CAA score 1,622 62 1.39 (1.01–1.90)* 77 1.17 (0.81–1.67)
Model 2}
CAA score
0 651 13 1.00 (reference) 18 1.00 (reference)
1 738 38 2.17 (1.09–4.30)* 44 1.46 (0.79–2.69)
2 180 9 1.93 (0.77–4.84) 8 0.85 (0.34–2.12)
3–4 18 1 1.59 (0.21–12.09) 4 3.40 (0.87–13.29)
Continuous
CAA score 1,587 61 1.32 (0.96–1.82) 74 1.14 (0.80–1.64)
N, number of participants; n, number of events; sHR, subdistribution hazard ratio; CI,
confidence interval; CAA, cerebral amyloid angiopathy.
Model 1: adjusted for age and sex.
Model 2: adjusted for age, sex, hypertension, cholesterol, lipid lowering medication,
history of atrial fibrillation, antithrombotic medication and APOE-ε2/ε4 carriership.
}Data missing for APOE-ε2/ε4 carriership n = 35.
*P < 0.05.
disease spectrum. CSVD is a spectrum referring to a group
of pathological processes with different mechanisms affecting
small arteries, veins and capillaries in the brain (43). Since these
pathologies partially co-occur and lead to similar markers in
different types of CSVD, there might be an overlap between
CSVD types and with CSVD and CAA scores and we might
not capture the pure disease type. Yet, depending on the setting,
to distinguish the pure disease type would be more desirable
for a clinical setting and to capture broad CSVD would be
more useful in a population-based setting. Conversely, CSVD,
and CAA scores are more likely to reach a ceiling effect within
patient populations, losing the granularity of individual markers,
whereas in a population-based setting theymay better capture the
cumulative effect and variability of subclinical disease. Another
way these scores could assist, is to detangle individual and
shared underlying mechanisms of CSVD biomarkers. Moreover,
reliable identification of asymptomatic CSVD with specific
markers could aid in selecting high risk individuals, monitoring
CSVD progression and predicting conversion of individuals from
asymptomatic to symptomatic CSVD (44).
Interestingly, we found no relation of strictly lobar
microbleeds with stroke and dementia, whereas we previously
found this in a larger population with microbleeds (23, 24). There
are several possible explanations for this. Firstly, the definitions
used for microbleeds differ, i.e., we separately categorized strictly
lobar microbleeds in the current study whereas in previous
studies “CAA-related” microbleeds were defined, which include
lobar microbleeds with or without cerebellar microbleeds.
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FIGURE 4 | Absolute risk estimates of stroke (A), dementia (B), and mortality (C) according to cerebral amyloid angiopathy score category over a period of 10 years.
N, number of participants; n, number of events. *Estimates calculated with competing risk modeling. †Estimates calculated with Cox modeling. *†Adjusted for age,
sex, hypertension, cholesterol, lipid lowering medication, history of atrial fibrillation, antithrombotic medication, and APOE-ε2/ε4 carriership.
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Secondly, we observed a small number of events per outcome for
the presence of strictly lobar microbleeds. The third explanation
is that microbleeds might be more acute markers and its
subclinical impact varies over time. Another study found that
while presence of strictly lobar microbleeds reflects CAA in
individuals without intracerebral hemorrhage, the diagnostic
accuracy of lobar microbleeds in the general population was
limited (45).
The modified Boston criteria are diagnostic criteria often used
in clinical practice and applied to identify other CAA biomarkers
in research (5). Application of these criteria in a non-selected
population should not be compared to its use in a clinical setting,
but we consider it of value to compare the performance of the
CAA score to the modified Boston criteria in terms of risk
prediction. In our population-based study, we found that the
CAA score estimated the relative risks for major neurological
outcomes and death better than the modified Boston criteria.
Recently, a review that summarized the validation of the Boston
criteria for probable CAA concluded that in a community-
based cohort the sensitivity was very low relative to hospital-
based cohorts (5, 45). This finding assumes that the current
set of criteria is insufficient to adequately identify probable
CAA in a subclinical setting. Presumably, CAA pathology has a
latent period during which CAA-related damage advances prior
to becoming severe enough to be diagnosed (5). Improving
the Boston criteria by incorporating non-hemorrhagic imaging
markers to better reflect CAA pathology on imaging is currently
a key issue for the future directions in diagnosis of CAA
(2, 5). Examples of such imaging markers are CSO-PVS,
WMH and cortical microinfarcts, or more advanced imaging
markers derived from diffusion tensor imaging (5, 7). The
diagnostic accuracy of the CAA score in combination with
pathological verification and the added value of new markers
should be evaluated to establish its practical use in research and
in clinics.
The strengths of our study are the longitudinal population-
based design and extensive data collection. However, several
limitations should also be considered. First, the CAA sum
score proposed by Charimidou et al. (14) used visual ratings of
WMH, whereas we used quantitative WMH volumes. Despite
this, quantitative and qualitative WMH assessments have been
shown to be acceptable in a population-based setting (46).
Although, we used our volumetric WMH data to approximate
the Fazekas scale, for clinical use a semi-quantitative rating
with the Fazekas scale would be more practical, as described
in the original CAA score (14, 47). Second, our CAA score
was defined as a simple addition of dichotomized imaging
markers with certain thresholds, which presume arbitrary
cut-offs andmay not reflect true biological processes. Specifically,
cut-offs based on counts could depend on imaging techniques
or scanner parameters, for example markers like CMB and
PVS. Potentially, using other methods to combine imaging
biomarkers, e.g., using machine learning techniques, could
have led to more informative markers and increased statistical
power. Yet, point-based scores such as the CAA sum score
are likely to be more practical in clinical and trial settings.
Third, the CAA score had an uneven distribution with fewer
events in participants with CAA scores of 3–4 due to the
small numbers of events in the long-term follow-up. Fourth, we
investigated cognitive deterioration in a cross-sectional design
with MMSE and g-factor which are crude global measures
of cognition. Longitudinal research will provide more robust
results and gain more insight in these findings. Also, healthier
participants without subjective memory complaints are more
likely to receive cognitive retesting during the study follow-
up which may have led to selection bias and influenced our
results. Nonetheless, in that case our results presumptively
would be biased toward the null. Fifth, although we aimed to
address potential confounders based on the literature, residual
confounding and unmeasured confounders may have affected
our results to some extent. Sixth, a definitive diagnosis of CAA
relies on pathological examination, yet obtaining pathological
confirmation was not feasible in our population-based setting.
Lastly, the majority of our population is Caucasian and
generalizability of our study results to other ethnicities is
therefore limited.
CONCLUSIONS
The results of this study in a community-dwelling population
indicate that a higher CAA score is related to cognitive
impairment and a higher risk of stroke, dementia, and mortality.
Our findings suggest that the practical use of the CAA score
to quantify the severity of vascular brain injury in an elderly
population could further assist etiologic or predictive research
purposes. Further evaluation of the score is needed to establish
its application in clinical practice.
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